Gabapentin Capsule
FDA Recall NDC 55154-7992

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 2 recorded enforcement report(s) associated with Gabapentin (NDC 55154-7992). A significant event, classified as Class II, was initiated on Oct 10, 2025 by Cardinal Health 107, Llc. The reported reason for this action was: "Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity ."

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

October 2025 Class II Recall: Failed Impurities/Degradation Specifications

Recall Number
Class II Ongoing
Reason for Recall
Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .
Initiated
Oct 10, 2025
Reported
Oct 29, 2025
Quantity
N/A

Recall Profile & Regulatory Data

Event ID
97777
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
The Harvard Drug Group LLC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide.
Product Description
Gabapentin Capsules, USP, 100 mg, 10 Capsules (10 x 1 blister pack), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, USA, NDC 0904-6665-61 (Blister pack), NDC 55154-3363-0 (Outer Bag).
Batch or Lot Expiration Information
Lot# M04989A [Bag], M04989 [Blister Pack], Exp Date: 02/2026
Lot# M05056A [Bag], M05056 [Blister Pack], Exp Date: 04/2026
Lot# M05150A [Bag], M05150 [Blister Pack], Exp Date: 07/2026
Lot# M05312A [Bag], M05312 [Blister Pack], and M05342A [Bag], M05342 [Blister Pack], Exp Date: 01/2027.
Affected Packages Involved in this Recall
0904-6665-61Product
0904-6666-61Product
0904-6667-61Product
55154-3363-0Product
55154-7992-0Product
55154-7993-0Product

June 2025 Class II Recall: Defective container; blister packaging inadequately sealed.

Recall Number
Class II Ongoing
Reason for Recall
Defective container; blister packaging inadequately sealed.
Initiated
Jun 19, 2025
Reported
Jul 09, 2025
Quantity
3,527 bags

Recall Profile & Regulatory Data

Event ID
97087
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
The Harvard Drug Group LLC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide
Product Description
Gabapentin Capsules, USP, 100 mg, 10 capsules (10x1) per bag, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN, 46268 USA, Distributed by Cardinal Health, Dublin, OH 43017, NDC 55154-3363-0
Batch or Lot Expiration Information
Lot# M05205A and M05205B, Exp Date 10/2026.
Affected Packages Involved in this Recall
55154-3363-0Product
55154-7992-0Product
55154-7993-0Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.